Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG-3019 in Liver Fibrosis Due to Chronic Hepatitis B
NCT01217632Phase 2Terminated
- Sponsor
- FibroGen
- Start
- Aug 2010
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Liver Fibrosis (LF) comparing FG-3019 with Placebo (2 arms). Primary endpoint: Efficacy of FG-3019 on liver fibrosis at 45 weeks. Started Aug 2010; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT01217632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217632.